AGC sells Colorado biopharmaceuticals CDMO sites, records ¥10.4B loss on sale

AGC sold its Colorado biopharmaceuticals CDMO sites and recorded a ¥10.4 billion loss on the sale.

Detected & updated continuously · Source: Nebula